Fluconazole versus itraconazole for the prevention of fungal infections in haemato-oncology.
Open Access
- 1 May 1999
- journal article
- clinical trial
- Published by BMJ in Journal of Clinical Pathology
- Vol. 52 (5) , 376-380
- https://doi.org/10.1136/jcp.52.5.376
Abstract
AIMS: To compare the efficacy of and tolerance to oral fluconazole and intraconazole in preventing fungal infection in neutropenic patients with haematological malignancies. PATIENTS: 213 consecutive, afebrile adult patients treated with or without autologous stem cell transplantation for haematological malignancies. METHODS: A randomised, double blind, single centre study. Patients were randomly assigned to receive fluconazole 50 mg or itraconazole 100 mg, both twice daily in identical capsules. An intention to treat analysis was performed on 202 patients, 101 in each group. RESULTS: Microbiologically documented systemic fungal infections occurred in four patients in each group. Clinical fungal infection was thought to be present in seven recipients of fluconazole and four of itraconazole. In all 202 patients, 29 proceeded to intravenous amphotericin (amphotericin B), 16 in the fluconazole group and 13 in the itraconazole group. Superficial fungal infection was seen only in three non-compliant patients in the fluconazole group. All these infections were oral. No major differences were noted in the isolates of fungi in mouth washes and fecal samples. Overall mortality was 8.9% (18 deaths; seven in the fluconazole group, 11 in the itraconazole group). Mortality from microbiologically and clinically documented fungal infection was 4.5% (nine deaths; three in the fluconazole group, six in the itraconazole group). Median time to suspected or proven fungal infection was 16 days in both groups. None of these comparisons reached statistical significance (p < 0.05). No major clinical toxicity was noted and compliance was excellent. CONCLUSIONS: In neutropenic patients treated for haematological malignancies with or without autologous stem cell transplantation, fluconazole and itraconazole in low doses result in a similar low frequency of fungal disease. Fluconazole may be the preferable drug because of the smaller number of capsules and lack of need for timing relative to meals.Keywords
This publication has 32 references indexed in Scilit:
- A meta-analysis of clinical studies of imipenem-cilastatin for empirically treating febrile neutropenic patientsJournal of Antimicrobial Chemotherapy, 1996
- Multiple dose pharmacokinetics of an oral solution of itraconazole in patients receiving chemotherapy for acute myeloid leukaemiaJournal of Antimicrobial Chemotherapy, 1995
- Multiple dose pharmacokinetics of an oral solution of itraconazole in autologous bone marrow transplant recipientsJournal of Antimicrobial Chemotherapy, 1994
- The prophylactic use of fluconazole 50 vs. 100 mg daily in haematological malignanciesEuropean Journal Of Cancer, 1993
- Efficacy of Itraconazole in the Prevention of Fungal Infections Among Neutropenic Patients with Hematologic Malignancies and Intensive Chemotherapy. A Double Blind, Placebo Controlled StudyLeukemia & Lymphoma, 1993
- A Controlled Trial of Fluconazole to Prevent Fungal Infections in Patients Undergoing Bone Marrow TransplantationNew England Journal of Medicine, 1992
- Imipenem‐cilastatin for empirical therapy in neutropenic patients with fever: An open study in patients with hematologic malignanciesEuropean Journal of Haematology, 1991
- Antifungal Prophylaxis with Itraconazole in Prolonged Neutropenia: Correlation with Plasma LevelsMycoses, 1989
- Empiric antifungal therapy in febrile granulocytopenic patientsThe American Journal of Medicine, 1989
- Oral anticandidal prophylaxis in patients undergoing chemotherapy for acute leukemiaMedical and Pediatric Oncology, 1977